EU/3/04/213: Orphan designation for the treatment of hypereosinophilic syndrome


Table of contents


On 29 July 2004, orphan designation (EU/3/04/213) was granted by the European Commission to SmithKline Beecham plc, United Kingdom, for mepolizumab for the treatment of hypereosinophilic syndrome.

The sponsorship was transferred to Glaxo Group Limited, United Kingdom, in September 2008.

The sponsorship was transferred to GlaxoSmithKline Trading Services Limited, Ireland, in May 2018.

The sponsor’s address was updated in April 2020. In April 2020, GlaxoSmithKline Trading Services Limited changed name to GlaxoSmithKline (Ireland) Limited.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in October 2020 on request of the Sponsor.

Key facts

Active substance
Intended use
Treatment of hypereosinophilic syndrome
Orphan designation status
EU designation number
Date of designation

GlaxoSmithKline (Ireland) Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
D24 YK11

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating